BSECompany Update4d ago · 16 Oct 2026, 02:59 pm

Please find the enclosed intimation of the Company as per the captioned subject for your reference.

AstraZeneca Pharma India Ltd · 506820

✦ AI SummaryESG

AstraZeneca Pharma India Ltd has been assigned an ESG rating of 73 by NSE Sustainability Ratings and Analytics Limited for financial year 2025-26.

Analysis Scores

Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Credit Rating

Attachments (1)

📄

d3181d29-8b79-46fc-a077-058a75f62007.pdf

pdf

Download →
View document text
October 16, 2026 The Manager – Listing BSE Limited P J Towers, Dalal Street, Fort, Mumbai – 400001 The Manager – Listing National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400051 Dear Sir/Madam, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Disclosure of ESG Rating With reference to the captioned subject, please note that NSE Sustainability Ratings and Analytics Limited has assigned an Environmental, Social and Governance (“ESG”) rating of 73 for the Company for financial year 2025-26. Please note that the Company has not engaged NSE Sustainability Ratings and Analytics Limited. NSE Sustainability Ratings and Analytics Limited has independently prepared their reporting based on publicly available information of the Company. Kindly take the above information on record. Thanking you, For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer ACS No.: A25784